Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study
Background:To investigate whether the introduction of modern third-generation chemotherapy was associated with survival benefits in a national population of patients with advanced non-small cell lung cancer (ANSCLC) and to explore geographical and temporary variations in the utilisation of chemother...
Gespeichert in:
| Veröffentlicht in: | Thorax 2008-10, Vol.63 (10), p.866-871 |
|---|---|
| Hauptverfasser: | , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 871 |
|---|---|
| container_issue | 10 |
| container_start_page | 866 |
| container_title | Thorax |
| container_volume | 63 |
| creator | von Plessen, C Strand, T-E Wentzel-Larsen, T Omenaas, E Wilking, N Sundstrøm, S Sörenson, S |
| description | Background:To investigate whether the introduction of modern third-generation chemotherapy was associated with survival benefits in a national population of patients with advanced non-small cell lung cancer (ANSCLC) and to explore geographical and temporary variations in the utilisation of chemotherapy.Methods:All patients with ANSCLC in the Cancer Registry of Norway during 1994–2005 were included. Using sales of vinorelbine as an indicator for chemotherapy, annual county utilisation rates were calculated. Survival before and after the general introduction of vinorelbine and associations between survival and variations in utilisation in counties were investigated. In a subgroup, the predictors of having received chemotherapy were explored.Results:Of 24 875 registered patients with lung cancer, 13 757 had ANSCLC. The annual utilisation of the indicator drug in Norway increased from 3.7 to 184.2 g (1998–2005). Median survival increased from 149 to176 days (p |
| doi_str_mv | 10.1136/thx.2007.093237 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_565024</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>69615677</sourcerecordid><originalsourceid>FETCH-LOGICAL-b505t-8df6b836940868f6dd0253d3749946c87ce6e40e428b5e0be0b64692dc10237d3</originalsourceid><addsrcrecordid>eNqFkd9vFCEQx4nR2Gv12TdDYvTBZK-w7ALrm7m01aQ5o9F7JSywPa77q8De9f4K_2XZ7uZMfDEhwDCfGWbmC8AbjJYYE3oZto_LFCG2RAVJCXsGFjijPCFpQZ-DBUIZSihh9Ayce79DCHGM2UtwhjkpECV4AX5fVZVRwe5Na7yHXQXD1jqd3EXbyWC7FqqtabqwjWZ_hNGOV-gHt7d7WY8BfcRMGzw82LCFUu9lq4yGbdcmvpF1DZWJWz20d1CNLgdtC9edO8jjJyhh-_RLTOXDoI-vwItK1t68ns8L8Ov66ufqS3L77ebr6vNtUuYoDwnXFS05oUWGOOUV1RqlOdGEZUWRUcWZMtRkyGQpL3ODyrhoRotUK4zinDS5AMmU1x9MP5Sid7aR7ig6acX8dB9vRuQ0R2kW-Q8T37vuYTA-iMb6sTHZmm7wghYU55SxCL77B9x1g4v9eYEZx4zlmI_U5UQp13nvTHUqACMxKiuismJUVkzKxoi3c96hbIz-y89SRuD9DEivZF25OGvrT1yKaCzv6eu5c-uDeTz5pbsXlBGWi_VmJW42m3Wx_rER3yP_ceLLZvffKv8A-UDKYA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1781775187</pqid></control><display><type>article</type><title>Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study</title><source>MEDLINE</source><source>BMJ Journals - NESLi2</source><source>Alma/SFX Local Collection</source><creator>von Plessen, C ; Strand, T-E ; Wentzel-Larsen, T ; Omenaas, E ; Wilking, N ; Sundstrøm, S ; Sörenson, S</creator><creatorcontrib>von Plessen, C ; Strand, T-E ; Wentzel-Larsen, T ; Omenaas, E ; Wilking, N ; Sundstrøm, S ; Sörenson, S</creatorcontrib><description>Background:To investigate whether the introduction of modern third-generation chemotherapy was associated with survival benefits in a national population of patients with advanced non-small cell lung cancer (ANSCLC) and to explore geographical and temporary variations in the utilisation of chemotherapy.Methods:All patients with ANSCLC in the Cancer Registry of Norway during 1994–2005 were included. Using sales of vinorelbine as an indicator for chemotherapy, annual county utilisation rates were calculated. Survival before and after the general introduction of vinorelbine and associations between survival and variations in utilisation in counties were investigated. In a subgroup, the predictors of having received chemotherapy were explored.Results:Of 24 875 registered patients with lung cancer, 13 757 had ANSCLC. The annual utilisation of the indicator drug in Norway increased from 3.7 to 184.2 g (1998–2005). Median survival increased from 149 to176 days (p<0.001). The adjusted hazard ratio (HR) for a diagnosis after the introduction was 0.93 (95% CI 0.88 to 0.99). County utilisation rates of vinorelbine (increments of 100 mg/1000 inhabitants) were inversely associated with the risk of death (HR 0.84, 95% CI 0.73 to 0.98). County of residence predicted chemotherapy utilisation with odds ratios in the range 0.13 (95% CI 0.1 to 0.19) to 1.04 (95% CI 0.64 to 1.69), a county with traditionally high utilisation as reference.Conclusion:Utilisation of third-generation chemotherapy was associated with slightly increased survival of patients with ANSCLC. Geographical and temporal differences in utilisation indicate variable quality of delivered care.</description><identifier>ISSN: 0040-6376</identifier><identifier>EISSN: 1468-3296</identifier><identifier>DOI: 10.1136/thx.2007.093237</identifier><identifier>PMID: 18390631</identifier><identifier>CODEN: THORA7</identifier><language>eng</language><publisher>London: BMJ Publishing Group Ltd and British Thoracic Society</publisher><subject>Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - mortality ; Cardiology. Vascular system ; Chemotherapy ; Clinical medicine ; Clinical trials ; Disease ; Drug Utilization Review ; Female ; Hospitals ; Humans ; Lung cancer ; Lung Neoplasms - drug therapy ; Lung Neoplasms - mortality ; Male ; Medical prognosis ; Medical sciences ; Metastasis ; Norway - epidemiology ; Patients ; Pharmaceutical industry ; Pharmacy ; Pneumology ; Public health ; Radiation therapy ; Survival Analysis ; Treatment Outcome ; Tumors of the respiratory system and mediastinum ; Vinblastine - administration & dosage ; Vinblastine - analogs & derivatives</subject><ispartof>Thorax, 2008-10, Vol.63 (10), p.866-871</ispartof><rights>2008 BMJ Publishing Group Ltd and the British Thoracic Society</rights><rights>2008 INIST-CNRS</rights><rights>Copyright: 2008 2008 BMJ Publishing Group Ltd and the British Thoracic Society</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-b505t-8df6b836940868f6dd0253d3749946c87ce6e40e428b5e0be0b64692dc10237d3</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://thorax.bmj.com/content/63/10/866.full.pdf$$EPDF$$P50$$Gbmj$$H</linktopdf><linktohtml>$$Uhttps://thorax.bmj.com/content/63/10/866.full$$EHTML$$P50$$Gbmj$$H</linktohtml><link.rule.ids>114,115,230,314,776,780,881,3183,23552,27903,27904,77346,77377</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=20667787$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/18390631$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:117678130$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>von Plessen, C</creatorcontrib><creatorcontrib>Strand, T-E</creatorcontrib><creatorcontrib>Wentzel-Larsen, T</creatorcontrib><creatorcontrib>Omenaas, E</creatorcontrib><creatorcontrib>Wilking, N</creatorcontrib><creatorcontrib>Sundstrøm, S</creatorcontrib><creatorcontrib>Sörenson, S</creatorcontrib><title>Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study</title><title>Thorax</title><addtitle>Thorax</addtitle><description>Background:To investigate whether the introduction of modern third-generation chemotherapy was associated with survival benefits in a national population of patients with advanced non-small cell lung cancer (ANSCLC) and to explore geographical and temporary variations in the utilisation of chemotherapy.Methods:All patients with ANSCLC in the Cancer Registry of Norway during 1994–2005 were included. Using sales of vinorelbine as an indicator for chemotherapy, annual county utilisation rates were calculated. Survival before and after the general introduction of vinorelbine and associations between survival and variations in utilisation in counties were investigated. In a subgroup, the predictors of having received chemotherapy were explored.Results:Of 24 875 registered patients with lung cancer, 13 757 had ANSCLC. The annual utilisation of the indicator drug in Norway increased from 3.7 to 184.2 g (1998–2005). Median survival increased from 149 to176 days (p<0.001). The adjusted hazard ratio (HR) for a diagnosis after the introduction was 0.93 (95% CI 0.88 to 0.99). County utilisation rates of vinorelbine (increments of 100 mg/1000 inhabitants) were inversely associated with the risk of death (HR 0.84, 95% CI 0.73 to 0.98). County of residence predicted chemotherapy utilisation with odds ratios in the range 0.13 (95% CI 0.1 to 0.19) to 1.04 (95% CI 0.64 to 1.69), a county with traditionally high utilisation as reference.Conclusion:Utilisation of third-generation chemotherapy was associated with slightly increased survival of patients with ANSCLC. Geographical and temporal differences in utilisation indicate variable quality of delivered care.</description><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - mortality</subject><subject>Cardiology. Vascular system</subject><subject>Chemotherapy</subject><subject>Clinical medicine</subject><subject>Clinical trials</subject><subject>Disease</subject><subject>Drug Utilization Review</subject><subject>Female</subject><subject>Hospitals</subject><subject>Humans</subject><subject>Lung cancer</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - mortality</subject><subject>Male</subject><subject>Medical prognosis</subject><subject>Medical sciences</subject><subject>Metastasis</subject><subject>Norway - epidemiology</subject><subject>Patients</subject><subject>Pharmaceutical industry</subject><subject>Pharmacy</subject><subject>Pneumology</subject><subject>Public health</subject><subject>Radiation therapy</subject><subject>Survival Analysis</subject><subject>Treatment Outcome</subject><subject>Tumors of the respiratory system and mediastinum</subject><subject>Vinblastine - administration & dosage</subject><subject>Vinblastine - analogs & derivatives</subject><issn>0040-6376</issn><issn>1468-3296</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2008</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNqFkd9vFCEQx4nR2Gv12TdDYvTBZK-w7ALrm7m01aQ5o9F7JSywPa77q8De9f4K_2XZ7uZMfDEhwDCfGWbmC8AbjJYYE3oZto_LFCG2RAVJCXsGFjijPCFpQZ-DBUIZSihh9Ayce79DCHGM2UtwhjkpECV4AX5fVZVRwe5Na7yHXQXD1jqd3EXbyWC7FqqtabqwjWZ_hNGOV-gHt7d7WY8BfcRMGzw82LCFUu9lq4yGbdcmvpF1DZWJWz20d1CNLgdtC9edO8jjJyhh-_RLTOXDoI-vwItK1t68ns8L8Ov66ufqS3L77ebr6vNtUuYoDwnXFS05oUWGOOUV1RqlOdGEZUWRUcWZMtRkyGQpL3ODyrhoRotUK4zinDS5AMmU1x9MP5Sid7aR7ig6acX8dB9vRuQ0R2kW-Q8T37vuYTA-iMb6sTHZmm7wghYU55SxCL77B9x1g4v9eYEZx4zlmI_U5UQp13nvTHUqACMxKiuismJUVkzKxoi3c96hbIz-y89SRuD9DEivZF25OGvrT1yKaCzv6eu5c-uDeTz5pbsXlBGWi_VmJW42m3Wx_rER3yP_ceLLZvffKv8A-UDKYA</recordid><startdate>20081001</startdate><enddate>20081001</enddate><creator>von Plessen, C</creator><creator>Strand, T-E</creator><creator>Wentzel-Larsen, T</creator><creator>Omenaas, E</creator><creator>Wilking, N</creator><creator>Sundstrøm, S</creator><creator>Sörenson, S</creator><general>BMJ Publishing Group Ltd and British Thoracic Society</general><general>BMJ</general><general>BMJ Publishing Group LTD</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>BTHHO</scope><scope>CCPQU</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>ADTPV</scope><scope>AOWAS</scope></search><sort><creationdate>20081001</creationdate><title>Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study</title><author>von Plessen, C ; Strand, T-E ; Wentzel-Larsen, T ; Omenaas, E ; Wilking, N ; Sundstrøm, S ; Sörenson, S</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-b505t-8df6b836940868f6dd0253d3749946c87ce6e40e428b5e0be0b64692dc10237d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2008</creationdate><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - mortality</topic><topic>Cardiology. Vascular system</topic><topic>Chemotherapy</topic><topic>Clinical medicine</topic><topic>Clinical trials</topic><topic>Disease</topic><topic>Drug Utilization Review</topic><topic>Female</topic><topic>Hospitals</topic><topic>Humans</topic><topic>Lung cancer</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - mortality</topic><topic>Male</topic><topic>Medical prognosis</topic><topic>Medical sciences</topic><topic>Metastasis</topic><topic>Norway - epidemiology</topic><topic>Patients</topic><topic>Pharmaceutical industry</topic><topic>Pharmacy</topic><topic>Pneumology</topic><topic>Public health</topic><topic>Radiation therapy</topic><topic>Survival Analysis</topic><topic>Treatment Outcome</topic><topic>Tumors of the respiratory system and mediastinum</topic><topic>Vinblastine - administration & dosage</topic><topic>Vinblastine - analogs & derivatives</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>von Plessen, C</creatorcontrib><creatorcontrib>Strand, T-E</creatorcontrib><creatorcontrib>Wentzel-Larsen, T</creatorcontrib><creatorcontrib>Omenaas, E</creatorcontrib><creatorcontrib>Wilking, N</creatorcontrib><creatorcontrib>Sundstrøm, S</creatorcontrib><creatorcontrib>Sörenson, S</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>BMJ Journals</collection><collection>ProQuest One Community College</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>SwePub</collection><collection>SwePub Articles</collection><jtitle>Thorax</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>von Plessen, C</au><au>Strand, T-E</au><au>Wentzel-Larsen, T</au><au>Omenaas, E</au><au>Wilking, N</au><au>Sundstrøm, S</au><au>Sörenson, S</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study</atitle><jtitle>Thorax</jtitle><addtitle>Thorax</addtitle><date>2008-10-01</date><risdate>2008</risdate><volume>63</volume><issue>10</issue><spage>866</spage><epage>871</epage><pages>866-871</pages><issn>0040-6376</issn><eissn>1468-3296</eissn><coden>THORA7</coden><abstract>Background:To investigate whether the introduction of modern third-generation chemotherapy was associated with survival benefits in a national population of patients with advanced non-small cell lung cancer (ANSCLC) and to explore geographical and temporary variations in the utilisation of chemotherapy.Methods:All patients with ANSCLC in the Cancer Registry of Norway during 1994–2005 were included. Using sales of vinorelbine as an indicator for chemotherapy, annual county utilisation rates were calculated. Survival before and after the general introduction of vinorelbine and associations between survival and variations in utilisation in counties were investigated. In a subgroup, the predictors of having received chemotherapy were explored.Results:Of 24 875 registered patients with lung cancer, 13 757 had ANSCLC. The annual utilisation of the indicator drug in Norway increased from 3.7 to 184.2 g (1998–2005). Median survival increased from 149 to176 days (p<0.001). The adjusted hazard ratio (HR) for a diagnosis after the introduction was 0.93 (95% CI 0.88 to 0.99). County utilisation rates of vinorelbine (increments of 100 mg/1000 inhabitants) were inversely associated with the risk of death (HR 0.84, 95% CI 0.73 to 0.98). County of residence predicted chemotherapy utilisation with odds ratios in the range 0.13 (95% CI 0.1 to 0.19) to 1.04 (95% CI 0.64 to 1.69), a county with traditionally high utilisation as reference.Conclusion:Utilisation of third-generation chemotherapy was associated with slightly increased survival of patients with ANSCLC. Geographical and temporal differences in utilisation indicate variable quality of delivered care.</abstract><cop>London</cop><pub>BMJ Publishing Group Ltd and British Thoracic Society</pub><pmid>18390631</pmid><doi>10.1136/thx.2007.093237</doi><tpages>6</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0040-6376 |
| ispartof | Thorax, 2008-10, Vol.63 (10), p.866-871 |
| issn | 0040-6376 1468-3296 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_565024 |
| source | MEDLINE; BMJ Journals - NESLi2; Alma/SFX Local Collection |
| subjects | Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - mortality Cardiology. Vascular system Chemotherapy Clinical medicine Clinical trials Disease Drug Utilization Review Female Hospitals Humans Lung cancer Lung Neoplasms - drug therapy Lung Neoplasms - mortality Male Medical prognosis Medical sciences Metastasis Norway - epidemiology Patients Pharmaceutical industry Pharmacy Pneumology Public health Radiation therapy Survival Analysis Treatment Outcome Tumors of the respiratory system and mediastinum Vinblastine - administration & dosage Vinblastine - analogs & derivatives |
| title | Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: a national study |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-27T12%3A51%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effectiveness%20of%20third-generation%20chemotherapy%20on%20the%20survival%20of%20patients%20with%20advanced%20non-small%20cell%20lung%20cancer%20in%20Norway:%20a%20national%20study&rft.jtitle=Thorax&rft.au=von%20Plessen,%20C&rft.date=2008-10-01&rft.volume=63&rft.issue=10&rft.spage=866&rft.epage=871&rft.pages=866-871&rft.issn=0040-6376&rft.eissn=1468-3296&rft.coden=THORA7&rft_id=info:doi/10.1136/thx.2007.093237&rft_dat=%3Cproquest_swepu%3E69615677%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1781775187&rft_id=info:pmid/18390631&rfr_iscdi=true |